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Changes in levels of catalase and glutathione in erythrocytes of
patients with stable asthma, treated with beclomethasone
dipropionate
H.J. Pennings*, P.J.A. Borm+, C.T.A. Evelo#, E.F.M. Wouters*
Changes in levels of catalase and glutathione in erythrocytes of patients with stable asth-
ma, treated with beclomethasone dipropionate. H.J. Pennings, P.J.A. Borm, C.T.A. Evelo,
E.F.M. Wouters. #ERS Journals Ltd 1999.
ABSTRACT: In asthmatic patients, antioxidant defence is decreased. Although in-
haled corticosteroids decrease asthmatic inflammation and modulate reactive oxygen
species (ROS) generation, little is known of their effect on cellular antioxidant levels.
The aim of this study was to evaluate the effect of inhaled beclomethasone dipro-
pionate (BDP; 1,000 mg.day-1) on erythrocyte antioxidant levels in stable asthmatic
patients.
Forty patients with stable, mild asthma were treated in a double-blind, placebo-
controlled, parallel-group study with BDP 250 mg, two puffs b.i.d. for 6 weeks. At
entry and every 2 weeks during treatment, erythrocyte antioxidant levels, haema-
tological parameters, pulmonary function tests and asthma symptoms were deter-
mined.
The results show that during treatment with BDP, erythrocyte catalase levels in-
creased (at entry (meanSEM) 414, after 6 weeks 544 mmol H2O2.min-1.g haemoglo-
bin (Hb)-1, p=0.05 in comparison with placebo). Erythrocyte total glutathione levels
significantly decreased after 6 weeks treatment with BDP (from 7.00.4 to 6.60.3
mmol.g Hb-1 (p=0.04)). In the BDP-treated patients, blood eosinophil counts were
higher in patients who responded with an increase in erythrocyte catalase levels dur-
ing BDP treatment, as compared to those not responding ((meanSEM) 34039 and
153526106 cells.L-1, respectively, p=0.05).
The present study shows that treatment with inhaled bedomethasone dipropionate
results in changes in antioxidant levels in erythrocytes of patients with stable, mild
asthma.
Eur Respir J 1999; 13: 1260±1266.
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Asthma is characterized by reversible airflow obstruc-
tion and the presence of a chronic inflammation within the
airways. Cells involved in the inflammatory process in
asthma have been shown to generate increased amounts of
reactive oxygen species (ROS) [1±3] and levels of ROS
generation correlate with asthma severity [4]. ROS-gener-
ation is enhanced in bronchoalveolar lavage (BAL) cells
of stable asthmatics [5] and increases after antigen chal-
lenge [6]. ROS can influence airway cell function by inter-
acting with deoxyribonucleic acid (DNA), altering protein
structures, interfering with signal transduction mecha-
nisms by oxidative modification (e.g. b2-adrenergic re-
ceptors), contracting airway smooth muscle, increasing
vascular permeability and increasing release of secondary
inflammatory mediators (i.e. leukotrienes, platelet-acti-
vating factor) [7]. Within the lung, powerful antioxidant
enzymes are present, both intra- and extracellularly, and
the levels of these enzymes may increase following chron-
ic exposure to increased levels of ROS [8, 9]. Levels of
glutathione have been shown to be elevated in BAL fluid
of patients with stable asthma [10]. In asthma, ROS gen-
eration is not only increased within the pulmonary com-
partment, but also in peripheral blood cells [1, 3]. This
observation is in line with data showing the presence of
activated leukocytes in the general circulation after aller-
gen challenge [11]. In asthma, evidence for a disturbed
oxidant±antioxidant balance has been found in the gen-
eral circulation. Decreased glutathione peroxidase levels
have been reported in serum, platelets and red blood cells
(RBC) [12, 13] and levels of selenium, a cofactor for
glutathioneperoxidase, are reduced in asthmatic patients
[13]. Decreased levels of catalase in RBC of asthmatic
children have also been reported [14]. Recently, it was
shown that the antioxidant capacity is decreased in
plasma of asthmatic patients, both in stable and in acute
asthma [15].
RBC can be regarded as circulating anti-oxidant car-
riers, reflecting exposition to ROS [9, 16]. The importance
of RBC antioxidant enzymes in protecting target cells
from ROS has been shown both in in vitro [17] and in
vivo [18] studies. RBC antioxidative enzymes can be det-
ermined with a high degree of reproducibility and studies
have shown that wide interindividual variations exist
[19]. Since RBC are more easily accessible than lung
tissue, RBC antioxidant levels have been used in studies
evaluating chronic ROS exposure [16, 20, 21].
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Corticosteroids play a dominant role in the treatment of
asthma owing to their powerful anti-inflammatory effects
[22]. So far, few studies have evaluated the effects of
inhaled corticosteroids on antioxidant levels in asthma
[23]. The aim of this study was to evaluate the influence
of inhaled beclomethasone dipropionate (BDP) on anti-
oxidant levels of RBC in patients with mild, stable asth-
ma. The changes were chosen to be studied in RBC, since




The present study was performed simultaneously with
investigations into the effect of BDP on isocapnic hyper-
ventilation with cold air, the results of which have been
reported previously [24]. Forty patients with mild, stable
asthma, equally distributed over both sexes, were includ-
ed in the study. The study design consisted of a double-
blind, placebo-controlled, parallel-group study, in which
patients were randomly allocated to receive either BDP
250 mg.puff-1, two puffs b.i.d. by metered-dose inhaler or
placebo (containing the propellant dichloride-difluoride-
methane and trichloride-fluoride-methane) for 6 weeks.
The time schedule consisted of a run-in period of 1 week,
followed by a treatment period of 6 weeks, during which
control visits were scheduled every 2 weeks. All patients
entering the study had a documented bronchial hyperre-
sponsiveness (defined as a provocative dose of histamine
causing a 20% fall in forced expiratory volume in one
second (PD20) value <8 mmol) and were all atopic, with a
mean number of positive skin tests for aeroallergens of
4.42.4 (meanSD).
Patients were all in a clinically stable condition and
showed no evidence of recent respiratory tract infection.
None of the patients had been treated with inhaled or oral
corticosteroids within the 3 months prior to the study. Only
b2-sympaticomimetic drugs were allowed for control of
asthma.
During the study, patients recorded in a diary, asthma
symptoms (0=no complaints, 5=major interference with
daily activities), the number of b2-sympaticomimetic drugs
used for control of asthma and peak expiratory flow rates
(PEFR), using mini-Wright peak-flow meters (Airmed;
Clement Clarke International Ltd., London, UK). Patients
recorded the best of three successive measurements of
PEFR in the morning and the evening. At every visit, the
patient diary was reviewed and pulmonary function was
evaluated by flow±volume measurements using a pneu-
motachograph (Masterlab, Jaeger, WuÈrzburg, Germany).
The study was approved by the local medical ethical
committee and written informed consent was obtained
from all patients.
Chemicals
The following chemicals were used: superoxide dis-
mutase (SOD; bovine erythrocytes), xanthine oxidase (cow
milk) and glutathione reductase (yeast) and reduced (GSH)
and oxidized (GSSG) glutathione (Boehringer Mannheim,
Mannheim, Germany); xanthine, cytochrome C, haemo-
globin (Hb), sodium azide and a-tocopherol (Merck,
Darmstadt, Germany); N-ethylmaleimide and o-phthal-
dialdehyde (Aldrich, Steinheim, Germany); 1-chloro-2,4-
dinitrobenzene (CDNB), glutathione reductase (GR; type
III) and reduced b-nicotinamide (NADPH) (Sigma, St
Louis, MO, USA, for the determination of glutathione/
glutathione S-transferase; Boehringer Mannheim for the
determination of glutathione peroxidase). All other chemi-
cals used were of analytical quality. Only microfiltrated
deionized water was used.
Venous blood preparation
Venous blood (15 mL) was collected in ethylenediomi-
netetraacetic acid (EDTA)-coated tubes (Sherwood Med-
ical, Balley-money, UK). White blood cell counts, cell
differentiation as well as quantification of eosinophils was
performed. For antioxidant analysis, blood was immedi-
ately stored at 48C after collection and processed within
2 h. Subsequently, blood was centrifuged for 10 min,
2,0006g at 48C. The buffy coat and plasma were removed
and the RBC were washed with 10 mL phosphate-buffered
saline (PBS), gently swirling the tube and afterwards RBC
were centrifuged again for 10 min, 2,0006g at 48C. This
procedure was repeated three times. After the washing
procedure, samples were frozen in aliquots of 1 mL at
-708C until analysis.
Glutathione peroxidase, superoxide dismutase and cat-
alase activity
The activity of these enzymes was determined as de-
scribed previously [20]. Haemoglobin was determined
according to the method of VAN KAMPEN and ZIJLSTRA
[25]. In brief, for glutathione peroxidase, 1 mL of haemo-
lysate was mixed with an equal volume of potassium
ferricyanide and KCN containing buffer. Fifty microlitres
of the mixture was added to the incubation buffer con-
taining 1 mM GSH, 200 mM NADPH and 1 IU.mL-1
GSSG-reductase and the rate of oxidation of NADPH was
followed for 3 min by spectrophotometry at 340 nM. The
substrate used was 0.33 mM H2O2 for measurement of
selenium dependent glutathione peroxidase. Units of enz-
yme activity were expressed as mmol NADPH.min-1.mg
Hb-1 using a molar extinction coefficient for NADPH of
6.22610-3.mM-1.cm-1.
Superoxide dismutase activity was measured by the
method of MCCORD and FRIDOVICH [26]. A standard curve
was prepared using commercially available SOD. The
enzyme activity at 258C was expressed in units of enzyme
per mg Hb.
Catalase activity was measured according to AEBI [27],
as described previously. Prior to the catalase measure-
ment, lysates were diluted to a concentration of 50 mg
Hb.mL-1. At 258C, 4 mL lysate and 1 mL H2O2 (30 mM)
were added to 2 mL PBS. The rapid decomposition of
H2O2 was followed during 15 s from the decrease in
absorbance at 240 nm. Enzyme activity was expressed as
mmol H2O2.min
-1.g Hb-1 using a molar extinction co-
efficient for H2O2 of 0.0394 mM
-1.cm-1.
Total glutathione (reduced plus oxidized) and glutathi-
one S-transferase were determined as described previous-
ly [21]. In brief, for determination of total glutathione,
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RBC were treated with an equal volume of 10% (w/v)
trichloroacetic acid. Supernatants were diluted 9-fold
with 100 mM sodium/potassium buffer (pH 7.4) and
measured using the cyclic oxidation-reduction method
essentially as described by ANDERSEN [28].
For determination of glutathione S-transferase (EC
2.5.1.18) activity with CDNB as a substrate, full lysis of
the thawed cells was induced with 5 volumes of ice-cold
water (10±15 min), using the method of HABIG and JACOBY
[29] with previously described modifications [30].
Statistics
All data described are meanSEM, unless otherwise
specified. Effect of treatment was expressed as changes
from baseline. Since antioxidant enzyme levels were not
distributed normally, nonparametric tests were used for
analysis between treatment groups (Mann±Whitney U-
test). A p-value <0.05 was considered statistically signifi-
cant (two-sided test). Correlations between parameters were
evaluated using the Spearman's rank correlation coeffi-
cient. The statistical package SPSS/PC+ (version 6.1-
Windows; SPSS Inc., Chicago, IL, USA) was used for all
calculations.
Results
Forty patients were included in the study. Demographic
variables are given in table 1. As reported previously,
patients in the BDP group demonstrated a significantly
higher FEV1 than the placebo group (101 versus 92%
predicted, p=0.02). Eighteen patients in the BDP group
and 17 patients in the placebo group completed the study.
In the placebo group, the main reason for dropping-out
was withdrawal of consent (three patients), whereas in the
BDP group exacerbation of eczema, necessitating oral
corticosteroid treatment (one patient) and noncompliance
(one patient) were the reasons for exclusion from the
study.
At baseline, no differences in RBC antioxidant enzymes
were observed between the groups (table 2). In the BDP
group, catalase levels could not be determined for two
patients due to technical reasons. Smoking patients were
equally distributed between groups (table 1); no diff-
erences in antioxidant levels were observed between
smokers and nonsmokers (data not shown). Furthermore,
no differences were observed in Hb, white blood cell
count and total number of eosinophils between the groups
(table 1). At entry, for the whole group a significant
positive correlation was observed between levels of
glutathione peroxidase and glutathione S-transferase (r=
0.51, p=0.001) and an inverse correlation for glutathione
peroxidase and SOD (r= -0.54, p<0.001). No significant
correlations were observed between levels of antioxidant
enzymes and baseline pulmonary function, levels of
bronchial hyperresponsiveness, immunoglobulin (Ig)E or
white blood cell parameters.
During treatment with BDP, a gradual increase in RBC
catalase activity was observed, which reached statistical
significance after 6 weeks (at entry (meanSEM) 414 mmol
H2O2.min
-1.g Hb-1, after 6 weeks 544 mmol H2O2.min-1.
g Hb-1, p=0.05) (figs. 1a and 2a). Interestingly, for total
RBC glutathione an opposite change was observed; dur-
ing BDP treatment, a gradual decrease in total glutathi-
one levels was observed, which also reached statistical
significance after 6 weeks of treatment (at entry (mean
SEM) 7.00.4 mmol.g Hb-1, at 6 weeks 6.60.3 mmol.g
Hb-1, p=0.04) (figs. 1b and 2b). No correlation was pres-
ent between changes in catalase and total glutathione in
RBC. However, the increase of RBC catalase activity
during treatment with BDP showed a weak inverse cor-
relation with the initial level of RBC catalase activity (r=
-0.51, p=0.04). For changes in total glutathione, a similar
trend was detected, although not statistically significant
(r= -0.42, p=0.08), Changes in the levels of catalase or
glutathione were not correlated with pulmonary function,
level of bronchial hyperresponsiveness or IgE. However,
when the BDP group was divided into responders (in-
crease in catalase at 6 weeks) and nonresponders (stable
or decreased catalase), a significant difference was obser-
ved between the two groups in the number of eosinophils
at entry (number of eosinophils at entry in nonrespond-
ers (meanSEM) 153526106 cells.L-1 versus responders
340396106 cells.L-1, p=0.05; fig. 3). No differences in
pulmonary function, airway hyperresponsiveness or base-
line antioxidant levels were present between responders
and nonresponders. For glutathione, no differences in the
Table 1. ± Subjects characteristics: anthropometric and
spirometric data
BDP group Placebo group
Sex M/F 10/10 10/10
Smokers yes/no 4/16 4/16
Age yrs 297 286
Height cm 1727 17212
Weight kg 7512 7414
FEV1 % pred 10112 9212
PD20 mmol 1.31.3 1.11.9
Haemoglobin mmol.L-1 8.70.6 9.10.8
Leukocytes 6109 cells.L-1 6.32.0 7.12.0
Eosinophils 6106 cells.L-1 318148 298229
IgE kU.L-1 430519 516911
Data are presented as meanSD. BDP: beclomethasone dipro-
pionate; M: male; F: female; FEV1: forced expiratory volume in
one second; PD20: provocative dose of histamine causing a 20%
fall in FEV1; IgE: immunoglobulin E. No significant differences
were observed between both groups of asthmatic patients,
except for FEV1, which was at baseline significantly higher in
the BDP group (p=0.02).
Table 2. ± Baseline red blood cell antioxidant levels in
asthmatic patients
BDP Placebo
SOD U.mg Hb-1 1.140.09 1.280.10
GP U.mg Hb-1 3.270.38 2.960.28
GST U.g Hb-1 1.940.14 1.850.15
Catalase mmol H2O2.min-1.g Hb-1 41.13.7 47.13.3
Total glutathione mmol.g Hb-1 7.010.35 6.270.25
Data are presented as meanSEM. BDP: beclomethasone dipro-
pionate; SOD: superoxide dismutase; Hb: haemoglobin; GP:
glutathione peroxidase; GST: glutathione-S-transferase. At base-
line, no significant differences were observed between the two
groups of asthmatic patients.
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number of eosinophils could be observed between
responders and nonresponders.
Activities of SOD, glutatione peroxidase and glutathione
S-transferase did not change during treatment with BDP
(data not shown). Also, during treatment with BDP, no
significant changes were observed in asthma symptom
scores, use of b2-rescue medication and pulmonary func-
tion, as reported previously [24].
During treatment with BDP, a significant decrease was
observed in the total number of eosinophils in peripheral
blood; this decrease was already observed after 2 weeks of
treatment (at entry (meanSEM) 318336106 cells.L-1;
after 2 weeks BDP 228316106 cells.L-1; p<0.02 betw-
een groups) and number of eosinophils remained well
below baseline levels during the rest of the study period
(fig. 4).
Discussion
The present study demonstrates that erythrocyte levels
of catalase increase and total glutathione levels decrease in
patients with mild stable asthma, treated with BDP. Addi-
tionally, treatment with BDP resulted in a significant
decrease in the total number of circulating eosinophils.
In asthma, numerous studies have shown that ROS are
involved in the inflammatory process [1±7]. Alveolar
macrophages of asthmatic patients demonstrated en-
hanced chemiluminescence, which correlated with asth-
ma severity and bronchial hyperresponsiveness [4, 5]. An
increased oxidative burden has been noted, not only in the
pulmonary compartment, but also in peripheral blood
cells which generate higher levels of ROS both spon-
taneously and after stimulation in comparison to healthy
controls. This has been observed for both blood poly-
morphonuclear neutrophils and monocytes [1, 2], and
also for blood eosinophils [3].
Antioxidant levels increase in response to oxidant
stress and can ameliorate oxidant induced injury [9]; know-
ledge of antioxidant defence levels is therefore essential
to predict total outcome of tissue damage. In asthma, it
has been shown that antioxidant levels are decreased,
both in the pulmonary compartment [23, 31] as well as in
peripheral blood [1, 12]. RBC have been used to monitor
long-term alterations in antioxidant status in chronic
pulmonary disorders [16, 20], as well as in asthma [14].
In the present study, treatment with BDP resulted in an



































































































Fig. 1. ± Beclomethasone dipropionate (BDP; 1,000 mg.day-1) induces
a significant rise in red blood cell (RBC) catalase levels (a) and a
decrease in RBC glutathione levels (b) of stable asthmatic patients after
6 weeks of treatment. Individual responses after 6 weeks of treatment are
shown for the BDP and placebo treated patients. Horizontal bars









































































































































































































































































































Fig. 2. ± Changes in time in a) red blood cell (RBC) catalase and b)
RBC glutathione in stable asthmatic patients, treated for 6 weeks with
beclomethasone dipropionate (BDP; 1,000 mg.day-1). Data are presen-
ted as meanSEM of the two treatment groups at entry (h), after two
weeks (k), four weeks (u) and after six weeks (r). *: p=0.05; +:
p=0.04, a significant difference after 6 weeks between the two groups.
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were observed in levels of glutathione peroxidase, SOD
and glutathione S-transferase. RBC express high levels of
catalase in contrast to, for instance, bronchial epithelial
cells [9]. Catalase is one of the most important mecha-
nisms by which RBC dispose of H2O2 [17] and RBC
catalase has been demonstrated to protect cells from ROS
burden [17]. Therefore, the increase in RBC catalase in
the present study reflects an increased defence against
ROS exposure. The observed negative correlation of base-
line catalase levels with the response of catalase to BDP
treatment, observed in the present study, leads to the
assumption that RBC catalase levels may be a marker of
the asthmatic inflammation, where lower levels of cata-
lase reflect enhanced exposure to ROS. Indeed in asth-
matic children, catalase levels have been shown to be
decreased in comparison to controls [14].
Several mechanisms may be involved in the effect of
BDP on RBC catalase. Treatment with BDP attenuates the
local inflammatory response as is shown in bronchial
biopsies [32] and BAL [33]. This may lead to a reduction
in the local formation of ROS. Recently, it was shown that
monocytes of asthmatic patients, treated with inhaled
steroids, produced less superoxide anions when stimu-
lated with phorbol myristate-acetate (PMA) in compari-
son with monocytes of untreated asthmatic patients [34].
Furthermore, inhaled corticosteroids may decrease levels
of inflammatory mediators, like transforming growth fac-
tor (TGF)-b, which normally inhibit antioxidant gene
activity [31], resulting in increased gene transcription.
Animal studies have shown that corticosteroids influ-
ence catalase gene-transcription. Dexamethasone has been
shown in vitro to increase catalase messenger ribonucleic
acid (mRNA) in perinatal rat lung cells [35] and to en-
hance SOD and glutathione peroxidase enzyme activity
in the foetal rat lung [36]. Administration of corticoster-
oids in vivo increased catalase and glutathione peroxidase
acti-vity in rat peritoneal macrophages and significantly
inhibited in vitro hydrogen peroxide production in peri-
toneal macrophages [37]. Effects of corticosteroids on
human cells are less clear. Although inhaled corticoster-
oids failed to influence ROS generation in stimulated
alveolar macrophages [33], corticosteroids significantly
reduced superoxide production in stimulated polymor-
phonuclear cells [38] and monocytes [34].
The present study also observed a reduction in RBC
total glutathione during treatment with BDP. Few data exist
regarding glutathione levels in RBC of asthmatic patients
[14]. Both animal and human studies have shown that
glutathione levels can increase during oxidant stress. In-
creased levels of glutathione were demonstrated in BAL
of asthmatic patients [10], in RBC of patients with chron-
ic occupational lung disorders [8] and in RBC of volun-
teers, participating in exercise training [21]. The decrease
in RBC glutathione, observed in the present study, may
therefore reflect decreased oxygen radical exposure. In-
deed, animal studies have observed that corticosteroids
decrease oxidative metabolism, followed by a decrease in
antioxidant enzyme levels [39]. Another explanation for
the observed decrease of total glutathione in the present
study may be that GSSG is transported out of the RBC;
however, this mechanism mainly occurs in heart and liver
cells [9] and is only observed in RBC when exposed to
very high levels of ROS. In addition, the observation of a
decrease in RBC glutathione indirectly argues against
systemic effects of inhaled BDP, since systemically ap-
plied corticosteroids have been shown in mice to increase
hepatic synthesis of glutathione [40].
The present study demonstrated that patients respond-
ing to BDP with an increase in catalase, had higher
eosinophil counts at entry than the patients not responding.
In addition, the present study supports data from a previous
study which also demonstrated a reduction in peripheral
blood eosinophils during treatment with inhaled corticos-
teroids [41]. Since the number of blood eosinophils have
been shown to correlate with asthma-severity [42], the
present study suggests that patients with higher levels of
inflammation show lower levels of RBC catalase and
higher blood eosinophil counts. The fact that the present
study did not observe changes in asthma-severity may be
explained by the relative insensitivity of these parameters

























































































































































Fig. 4. ± Beclomethasone dipropionate (BDP) induces a significant
decrease in the number of circulating eosinophils in stable asthmatic
patients. Data are presented as meanSEM of the number of blood
eosinophils during treatment with BDP or placebo. Data are for entry
into study (h), after two weeks (k), four weeks (u) and after six weeks

























Response of catalase to BDP
Nonresponders Responders
*
Fig. 3. ± Boxplots (5th, 25th, 50th, 75th and 95th percentiles) showing
that the number of peripheral blood eosinophils in responders (patients
responding with a rise in red blood cell (RBC) catalase after beclo-
methasone dipropionate (BDP) treatment; n=13) was significantly high-
er than in nonresponders (i.e. stable or decreased catalase levels; n=3).
*: p=0.05.
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In conclusion, the present study demonstrates that in
patients with mild, stable asthma, treatment with inhaled
beclomethasone dipropionate results in an increase in red
blood cell catalase levels and, at the same time, a decrease
in red blood cell glutathione. Peripheral blood eosinophil
counts were higher in patients who demonstrated an in-
crease in red blood cell catalase during treatment with
beclomethasone dipropionate. It is speculated that inhaled
beclomethasone dipropionate decreases reactive oxygen
species generation within the lung, which leads to a sub-
sequent change in systemic antioxidant levels. Further
studies, simultaneously evaluating reactive oxygen species
formation within the lung while monitoring antioxidant
defences, will be needed in order to improve the under-
standing of the effects of inhaled corticosteroids on
antioxidant defences in asthma.
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